Campbell & Co Investment Adviser’s BridgeBio Pharma BBIO Stock Holding History

Campbell & Co Investment Adviser’s Portfolio BBIO Stock Details BBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-35,053	Closed	-$1.51M	–	1088
2025 Q2	$1.51M	Buy	+35,053	New	+$1.27M	0.1%	335
2024 Q1	–	Sell	-23,071	Closed	-$931K	–	1106
2023 Q4	$931K	Buy	23,071 +7,775	+51%	+$234K	0.08%	418
2023 Q3	$403K	Buy	+15,296	New	+$434K	0.05%	608

Other funds holding BBIO

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

KKRC

Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

ACM

Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Campbell & Co Investment Adviser's BBIO Position: Q3 2025 in Review

Campbell & Co Investment Adviser sold out of BridgeBio Pharma (BBIO) in Q3 2025, closing a stake of 35,053 shares — an estimated $1.51M sold.

Campbell & Co Investment Adviser first reported a position in BBIO in Q3 2023 and held it in 3 quarters. The position peaked at $1.51M in Q2 2025. 392 funds tracked by Wall St. Rank hold BBIO as of Q3 2025.

Campbell & Co Investment Adviser reported no remaining BridgeBio Pharma position as of Q3 2025 after selling out during the quarter.
Campbell & Co Investment Adviser sold 35,053 BridgeBio Pharma shares in Q3 2025, an estimated $1.51M.
Campbell & Co Investment Adviser first reported a position in BridgeBio Pharma in Q3 2023 and held it in 3 quarters.
Campbell & Co Investment Adviser's BridgeBio Pharma position peaked at $1.51M in Q2 2025.
392 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q3 2025.

Based on Campbell & Co Investment Adviser's 13F filing for Q3 2025, filed 28 Oct 2025.